Docrates Cancer Center celebrates its 15th anniversary – one step ahead of cancer

Docrates’ services have taken huge steps since the year it was established. The hospital offered its first cancer treatments in October 2007. The aim of providing patients with state-of-the-art cancer therapies has guided the cancer center’s operations from the very beginning. In addition to cytostatic therapy, radiotherapy and surgical treatment, Docrates utilises modern and patient-specific immuno-oncological therapies, drugs selected on the basis of genetic changes and radioisotope treatments.

Over the years, the hospital has invested in next-generation technology and imaging equipment, which have been designed to meet the demands of cancer diagnostics and individual treatment.

– With the technology and actively utilised genetics and molecular information, Docrates can take advantage of targeted diagnostics and find courses of treatment that are still waiting to be introduced elsewhere. Our cancer hospital uses, for example, the high-end technology PET-CT scanner and 3-tesla magnetic resonance imaging scanner, which allow us to make even more specific diagnoses and create more individualised treatment plans, says Ilpo Tolonen, CEO of Docrates Cancer Center.

Of our patients, 92% are very satisfied with the care and service we provide at Docrates. According to customer feedback received in 2021, the customer loyalty indicator, Net Promoter Score (NPS), was 90%.

Important milestones in cancer treatment

Important milestones reached in the adoption of the latest cancer treatment methods at the hospital include, for example, the first immunotherapy treatment in breast cancer in Finland in 2015, and radiopharmaceutical therapy in treating metastatic prostate cancer was introduced in 2017. Radiopharmaceutical therapy makes it possible to effectively destroy metastases outside the bone structures and in bone metastases, without serious adverse effects.

Docrates is also using the latest treatments for breast cancer, such as trastuzumab deruxtecan and sacituzumab govitecan, which prolong survival in patients with advanced breast cancer. These treatment methods also alleviate symptoms and allow for more patients to be treated.

Our personnel are dedicated to helping and supporting our patients

Docrates employs close to 100 motivated experts who are committed to treating patients in accordance with the hospital’s value proposition: as one human being to another. The hospital invests in internationalisation and serves its customer in nine different languages. Each patient has their own designated personal doctor and care team, who are available and present every step of the way along the treatment path, offering all the necessary information and support in the patient’s new situation in life.

– Over the years, we have developed our hospital by expanding as well as through recruiting specialists and investing in state-of-the-art equipment and drug therapies. It is important for us that our patients are required to wait after cancer is suspected or has already been diagnosed, but they have access to thorough examinations and treatment without delay. Treatment follow-up is carried out through a digital service which regularly measures the quality of life. Through our prompt customer service, we aim to minimise the risk of the aggressive cancer spreading, as well as the suffering caused by waiting. The use of our extensive early cancer detection models has considerably increased over the years,” says Ilpo Tolonen.

 For more information, please contact:
Anna-Sofia Malmi, Marketing and Communications Director
tel. +358 50 4690 114, anna-sofia.malmi@docrates.com